Nicolai Obling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nicolai Obling has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Uffe Bodtger
Respiratory Research Unit PLUZ, Department of Internal and Respiratory Medicine, Zealand University Hospital, 4700 Næstved, Denmark
6 shared publications Vibeke Backer
Center for Physical Activity Research, Rigshospitalet, Copenhagen University, Denmark; Department of ENT, Rigshospitalet, Copenhagen University, Copenhagen, Denmark
5 shared publications- John R. Hurst
University College London
3 shared publications John R Hurst
UCL Respiratory, University College London, London, United Kingdom
2 shared publicationsAbir Nasr
Respiratory Medicine and Allergology, Clinical Sciences Lund, Lund University, Lund, Sweden
1 shared publication- Alexander Silberbrandt
Bispebjerg Hospital, Copenhagen , Denmark
1 shared publication
Latest Publications
- Open Access
- 27 October 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (2)
Distribution of type 2 biomarkers and association with severity, clinical characteristics and comorbidities in the BREATHE real-life asthma population
Background: Type 2 (T2) high asthma is recognised as a heterogenous entity consisting of several endotypes; however, the prevalence and distribution of the T2 biomarkers in the general asthma population, across asthma severity, and across compartments is largely unknown. The objective of the present study was to describe expression and overlaps of airway and systemic T2 biomarkers in a clinically representative asthma population.Methods: Patients with asthma from the real-life BREATHE cohort referred to a specialist centre were included and grouped according to T2 biomarkers: blood and sputum eosinophilia (≥0.3×109 cells·L−1and 3% respectively), total IgE (≥150 U·mL−1), and fractional exhaled nitric oxide (≥25 ppb).Results: Patients with mild-to-moderate asthma were younger (41versus49 years, pversus28.0 kg·m−2, p=0.002) and less atopy (47%versus58%, p=0.05), higher forced expiratory volume in 1 s (3.2versus2.8 L, pversus3.9 L, p9versus0.17×109 cells·L−1, p=0.01) and sputum (3.0%versus1.5%, p=0.01) eosinophils. Co-expression of all T2 biomarkers was a particular characteristic of severe asthma (p<0.001). In patients with eosinophilia, sputum eosinophilia without blood eosinophilia was present in 45% of patients with mild-to-moderate asthma and 35% with severe asthma.Conclusion: Severe asthma is more commonly associated with activation of several T2 pathways, indicating that treatments targeting severe asthma may need to act more broadly on T2 inflammatory pathways. Implementation of airway inflammometry in clinical care is of paramount importance, as the best treatable trait is otherwise is overlooked in a large proportion of patients irrespective of disease severity.
- 27 October 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (2)
Open AccessDistribution of type 2 biomarkers and association with severity, clinical characteristics and comorbidities in the BREATHE real-life asthma population
Background: Type 2 (T2) high asthma is recognised as a heterogenous entity consisting of several endotypes; however, the prevalence and distribution of the T2 biomarkers in the general asthma population, across asthma severity, and across compartments is largely unknown. The objective of the present study was to describe expression and overlaps of airway and systemic T2 biomarkers in a clinically representative asthma population.Methods: Patients with asthma from the real-life BREATHE cohort referred to a specialist centre were included and grouped according to T2 biomarkers: blood and sputum eosinophilia (≥0.3×109 cells·L−1and 3% respectively), total IgE (≥150 U·mL−1), and fractional exhaled nitric oxide (≥25 ppb).Results: Patients with mild-to-moderate asthma were younger (41versus49 years, pversus28.0 kg·m−2, p=0.002) and less atopy (47%versus58%, p=0.05), higher forced expiratory volume in 1 s (3.2versus2.8 L, pversus3.9 L, p9versus0.17×109 cells·L−1, p=0.01) and sputum (3.0%versus1.5%, p=0.01) eosinophils. Co-expression of all T2 biomarkers was a particular characteristic of severe asthma (p<0.001). In patients with eosinophilia, sputum eosinophilia without blood eosinophilia was present in 45% of patients with mild-to-moderate asthma and 35% with severe asthma.Conclusion: Severe asthma is more commonly associated with activation of several T2 pathways, indicating that treatments targeting severe asthma may need to act more broadly on T2 inflammatory pathways. Implementation of airway inflammometry in clinical care is of paramount importance, as the best treatable trait is otherwise is overlooked in a large proportion of patients irrespective of disease severity.
- Open Access
- 22 February 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 195, 106774
Nasal and systemic inflammation in Chronic Obstructive Pulmonary Disease (COPD)
- 22 February 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 195, 106774
Open AccessNasal and systemic inflammation in Chronic Obstructive Pulmonary Disease (COPD)
- Open Access
- 1 January 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 191, 106710
Upper airway symptoms and Small Airways Disease in Chronic Obstructive Pulmonary Disease, COPD
- 1 January 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 191, 106710
Open AccessUpper airway symptoms and Small Airways Disease in Chronic Obstructive Pulmonary Disease, COPD
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3426
Small Airways Disease and Emphysema (Assessed by High-Resolution CT) and Symptom Burden in COPD
Background: Small airways disease (SAD) and emphysema contribute to symptom burden in COPD. In this study, we sought to examine the prevalence of SAD and emphysema in a cohort of COPD patients and to investigate associations with lower and upper airway symptoms. In asthma, SAD and upper airways symptoms are associated. Methods: We examined patients from the BREATHE cohort with High-Resolution CT (HRCT) and subsequent Parametric Response Mapping (PRM) analysis and recorded distribution of emphysema (EmpPRM) and functional Small Airways Disease (fSADPRM). We evaluated upper and lower airway symptoms using the Upper Airway subdomain of the 22 items Sino Nasal Outcome Test (SNOT22UAS, cut-off ≥ 6 points) and the COPD Assessment Test (CAT), respectively. Dynamic and static lung function tests were measured. Findings: Sixty patients were enrolled (female sex: 52%, age: 67 (±8.3) years, FEV1%predicted: 50.3% (±17.8%), GOLD stage: A: 16%, B: 53%, D: 30%). 22 patients (36%) reported significant upper airway symptoms. The mean levels of EmpPRM and fSADPRM were 25.1% (±13.3%) and 39.5% (±5.2%) respectively. We found no significant association between HRCT scores (EmpPRM or fSADPRM) and symptom burden (CAT score or SNOT22UAS), despite both HRCT scores correlating significantly and positively with hyperinflation (Residual Volume and Total Lung Capacity) and negatively with FEV1 and diffusion capacity. Conclusion: Functional small airways disease and emphysema are widespread features of COPD, but in the current study not clearly associated with symptom burden.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA3426
Small Airways Disease and Emphysema (Assessed by High-Resolution CT) and Symptom Burden in COPD
Background: Small airways disease (SAD) and emphysema contribute to symptom burden in COPD. In this study, we sought to examine the prevalence of SAD and emphysema in a cohort of COPD patients and to investigate associations with lower and upper airway symptoms. In asthma, SAD and upper airways symptoms are associated. Methods: We examined patients from the BREATHE cohort with High-Resolution CT (HRCT) and subsequent Parametric Response Mapping (PRM) analysis and recorded distribution of emphysema (EmpPRM) and functional Small Airways Disease (fSADPRM). We evaluated upper and lower airway symptoms using the Upper Airway subdomain of the 22 items Sino Nasal Outcome Test (SNOT22UAS, cut-off ≥ 6 points) and the COPD Assessment Test (CAT), respectively. Dynamic and static lung function tests were measured. Findings: Sixty patients were enrolled (female sex: 52%, age: 67 (±8.3) years, FEV1%predicted: 50.3% (±17.8%), GOLD stage: A: 16%, B: 53%, D: 30%). 22 patients (36%) reported significant upper airway symptoms. The mean levels of EmpPRM and fSADPRM were 25.1% (±13.3%) and 39.5% (±5.2%) respectively. We found no significant association between HRCT scores (EmpPRM or fSADPRM) and symptom burden (CAT score or SNOT22UAS), despite both HRCT scores correlating significantly and positively with hyperinflation (Residual Volume and Total Lung Capacity) and negatively with FEV1 and diffusion capacity. Conclusion: Functional small airways disease and emphysema are widespread features of COPD, but in the current study not clearly associated with symptom burden.
- Open Access
- 25 June 2021
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 7 (3)
Upper airway symptoms associate with the eosinophilic phenotype of COPD
Background: There is growing evidence that upper airway symptoms coexist with lower airway symptoms in COPD. Still, the prevalence and impact of upper airway disease on the nature and course of COPD remain unclear. We aimed to describe this in a cross-sectional study.Methods: We examined a cohort of COPD patients with pulmonary function tests, induced sputum, blood eosinophils, atopy tests and computed tomography (CT) of the paranasal sinuses. Lower airway symptoms were assessed using the COPD Assessment Test (CAT), and upper airway symptoms were assessed using the nasal subdomain of the 22-item Sino Nasal Outcome Test (SNOT22nasal). We recruited patients from five sites in Denmark and Sweden. We excluded patients with a history of asthma.Findings: In total, 180 patients (female 55%, age 67±8 years, forced expiratory volume in 1 s (FEV1%) 52.4±16.6, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage: A: 18%, B: 54%, C: 3%, D: 25%) were included in the study. Seventy-four patients (41%) reported high upper airway symptoms (UAS, defined as SNOT22nasal≥6) with a median score of 10 (IQR 8–13). Patients with high UAS reported higher CAT scores (17.4±7.5versus14.9±6.6, pversus2.3% (IQR 1.4–3.1%), pversusmedian 0.5% (IQR 0–1.7%), p<0.05). No differences in atopy, CT findings or exacerbation rates were observed.Conclusion: COPD patients with upper airway disease showed increased evidence of eosinophilic disease and increased lower airway symptom burden.
- 25 June 2021
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 7 (3)
Open AccessUpper airway symptoms associate with the eosinophilic phenotype of COPD
Background: There is growing evidence that upper airway symptoms coexist with lower airway symptoms in COPD. Still, the prevalence and impact of upper airway disease on the nature and course of COPD remain unclear. We aimed to describe this in a cross-sectional study.Methods: We examined a cohort of COPD patients with pulmonary function tests, induced sputum, blood eosinophils, atopy tests and computed tomography (CT) of the paranasal sinuses. Lower airway symptoms were assessed using the COPD Assessment Test (CAT), and upper airway symptoms were assessed using the nasal subdomain of the 22-item Sino Nasal Outcome Test (SNOT22nasal). We recruited patients from five sites in Denmark and Sweden. We excluded patients with a history of asthma.Findings: In total, 180 patients (female 55%, age 67±8 years, forced expiratory volume in 1 s (FEV1%) 52.4±16.6, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage: A: 18%, B: 54%, C: 3%, D: 25%) were included in the study. Seventy-four patients (41%) reported high upper airway symptoms (UAS, defined as SNOT22nasal≥6) with a median score of 10 (IQR 8–13). Patients with high UAS reported higher CAT scores (17.4±7.5versus14.9±6.6, pversus2.3% (IQR 1.4–3.1%), pversusmedian 0.5% (IQR 0–1.7%), p<0.05). No differences in atopy, CT findings or exacerbation rates were observed.Conclusion: COPD patients with upper airway disease showed increased evidence of eosinophilic disease and increased lower airway symptom burden.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Upper Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease
Background: There is growing evidence that nasal symptoms coexist with lower respiratory symptoms in Chronic Obstructive Pulmonary Disease (COPD), but prevalence and impact on nature and course of COPD remains unclear. We aimed to describe this in a real-life, non-randomized, observational study. Methods: In this study, we examined a cohort of patients with confirmed COPD (Post-BD FEV1/FVC 0.01). Patients with nasal symptoms also displayed significantly higher levels of eosinophils in induced sputum (median 2.9% (IQR 1.6-4.8) vs. 2.4 (IQR 1.4-3.1)) and blood (median 1.91 (IQR 0.3-7.1) vs. median 0.56 (IQR 0-1.9)). No significant differences observed in the prevalence of atopy, in pulmonary function tests or in the rate of exacerbations. Conclusion: Nasal symptoms were prevalent among COPD patients and were associated with eosinophilia and increased COPD symptom burden.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Upper Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease
Background: There is growing evidence that nasal symptoms coexist with lower respiratory symptoms in Chronic Obstructive Pulmonary Disease (COPD), but prevalence and impact on nature and course of COPD remains unclear. We aimed to describe this in a real-life, non-randomized, observational study. Methods: In this study, we examined a cohort of patients with confirmed COPD (Post-BD FEV1/FVC 0.01). Patients with nasal symptoms also displayed significantly higher levels of eosinophils in induced sputum (median 2.9% (IQR 1.6-4.8) vs. 2.4 (IQR 1.4-3.1)) and blood (median 1.91 (IQR 0.3-7.1) vs. median 0.56 (IQR 0-1.9)). No significant differences observed in the prevalence of atopy, in pulmonary function tests or in the rate of exacerbations. Conclusion: Nasal symptoms were prevalent among COPD patients and were associated with eosinophilia and increased COPD symptom burden.
- 13 January 2020
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 74 (3) , 181-186
Screening for obstructive lung disease in hospitalized psychiatric patients
Objective: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality worldwide and it remains under-diagnosed. Unrecognized somatic disease contributes significantly to the observed increased mortality rate in patients with psychiatric diseases. Aims: To investigate whether screening with spirometry and simple questions on respiratory symptoms were efficacious in identifying previously unknown cases of COPD and/or asthma in patients admitted to psychiatric wards. Methods: In this observational cohort study, we included hospitalized psychiatric patients in2013. All were assessed with handheld spirometry, medical history and completion of a simple, short questionnaire on respiratory symptoms, the COPD assessment test (CAT questionnaire). Results: In total, 106 patients were screened and 45 patients (age: median 45, range 19–75, 43% female gender) were included whereas 61 patients (age: median 42, range 19–73) 34% female gender) were excluded. Prior to screening three patients (6.5%) reported having a diagnosis of COPD whereas eight patients (17%) reported having a diagnosis of asthma. Six new cases were diagnosed with COPD and four new cases with asthma. The number needed to screen to find one new case was 3.4 (total cohort 4.5). Conclusion: We present a simple study where the patients are screened for obstructive lung disease with a handheld spirometry and a questionnaire on respiratory symptoms. Number needed to screen is low at 3.4–4.5. In all, 10 new cases of obstructive lung disease were diagnosed. This study illustrates that screening for COPD and asthma is feasible even in a psychiatric population.
- 13 January 2020
- Published by Taylor & Francis in Nordic Journal of Psychiatry
- Vol. 74 (3) , 181-186
Screening for obstructive lung disease in hospitalized psychiatric patients
Objective: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality worldwide and it remains under-diagnosed. Unrecognized somatic disease contributes significantly to the observed increased mortality rate in patients with psychiatric diseases. Aims: To investigate whether screening with spirometry and simple questions on respiratory symptoms were efficacious in identifying previously unknown cases of COPD and/or asthma in patients admitted to psychiatric wards. Methods: In this observational cohort study, we included hospitalized psychiatric patients in2013. All were assessed with handheld spirometry, medical history and completion of a simple, short questionnaire on respiratory symptoms, the COPD assessment test (CAT questionnaire). Results: In total, 106 patients were screened and 45 patients (age: median 45, range 19–75, 43% female gender) were included whereas 61 patients (age: median 42, range 19–73) 34% female gender) were excluded. Prior to screening three patients (6.5%) reported having a diagnosis of COPD whereas eight patients (17%) reported having a diagnosis of asthma. Six new cases were diagnosed with COPD and four new cases with asthma. The number needed to screen to find one new case was 3.4 (total cohort 4.5). Conclusion: We present a simple study where the patients are screened for obstructive lung disease with a handheld spirometry and a questionnaire on respiratory symptoms. Number needed to screen is low at 3.4–4.5. In all, 10 new cases of obstructive lung disease were diagnosed. This study illustrates that screening for COPD and asthma is feasible even in a psychiatric population.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in European Clinical Respiratory Journal
- Vol. 7 (1) , 1736934
Clinical characteristics of the BREATHE cohort – a real-life study on patients with asthma and COPD
Background: The BREATHE study is a cross-sectional study of real-life patients with asthma and/or COPD in Denmark and Sweden aiming to increase the knowledge across severities and combinations of obstructive airway disease. Design: Patients with suspicion of asthma and/or COPD and healthy controls were invited to participate in the study and had a standard evaluation performed consisting of questionnaires, physical examination, FeNO and lung function, mannitol provocation test, allergy test, and collection of sputum and blood samples. A subgroup of patients and healthy controls had a bronchoscopy performed with a collection of airway samples. Results: The study population consisted of 1403 patients with obstructive airway disease (859 with asthma, 271 with COPD, 126 with concurrent asthma and COPD, 147 with other), and 89 healthy controls (smokers and non-smokers). Of patients with asthma, 54% had moderate-to-severe disease and 46% had mild disease. In patients with COPD, 82% had groups A and B, whereas 18% had groups C and D classified disease. Patients with asthma more frequently had childhood asthma, atopic dermatitis, and allergic rhinitis, compared to patients with COPD, asthma + COPD and Other, whereas FeNO levels were higher in patients with asthma and asthma + COPD compared to COPD and Other (18 ppb and 16 ppb vs 12.5 ppb and 14 ppb, p < 0.001). Patients with asthma, asthma + COPD and Other had higher sputum eosinophilia (1.5%, 1.5%, 1.2% vs 0.75%, respectively, p < 0.001) but lower sputum neutrophilia (39.3, 43.5%, 40.8% vs 66.8%, p < 0.001) compared to patients with COPD. Conclusions: The BREATHE study provides a unique database and biobank with clinical information and samples from 1403 real-life patients with asthma, COPD, and overlap representing different severities of the diseases. This research platform is highly relevant for disease phenotype- and biomarker studies aiming to describe a broad spectrum of obstructive airway diseases.
- 1 January 2020
- Published by Taylor & Francis in European Clinical Respiratory Journal
- Vol. 7 (1) , 1736934
Open AccessClinical characteristics of the BREATHE cohort – a real-life study on patients with asthma and COPD
Background: The BREATHE study is a cross-sectional study of real-life patients with asthma and/or COPD in Denmark and Sweden aiming to increase the knowledge across severities and combinations of obstructive airway disease. Design: Patients with suspicion of asthma and/or COPD and healthy controls were invited to participate in the study and had a standard evaluation performed consisting of questionnaires, physical examination, FeNO and lung function, mannitol provocation test, allergy test, and collection of sputum and blood samples. A subgroup of patients and healthy controls had a bronchoscopy performed with a collection of airway samples. Results: The study population consisted of 1403 patients with obstructive airway disease (859 with asthma, 271 with COPD, 126 with concurrent asthma and COPD, 147 with other), and 89 healthy controls (smokers and non-smokers). Of patients with asthma, 54% had moderate-to-severe disease and 46% had mild disease. In patients with COPD, 82% had groups A and B, whereas 18% had groups C and D classified disease. Patients with asthma more frequently had childhood asthma, atopic dermatitis, and allergic rhinitis, compared to patients with COPD, asthma + COPD and Other, whereas FeNO levels were higher in patients with asthma and asthma + COPD compared to COPD and Other (18 ppb and 16 ppb vs 12.5 ppb and 14 ppb, p < 0.001). Patients with asthma, asthma + COPD and Other had higher sputum eosinophilia (1.5%, 1.5%, 1.2% vs 0.75%, respectively, p < 0.001) but lower sputum neutrophilia (39.3, 43.5%, 40.8% vs 66.8%, p < 0.001) compared to patients with COPD. Conclusions: The BREATHE study provides a unique database and biobank with clinical information and samples from 1403 real-life patients with asthma, COPD, and overlap representing different severities of the diseases. This research platform is highly relevant for disease phenotype- and biomarker studies aiming to describe a broad spectrum of obstructive airway diseases.